arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Immuneering Corp

IMRX

$4.52 ▲ +0.06 (+1.35%) at close

7 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Immuneering Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $198.9M

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -21.5% ↗

FCF / Share $-1.03 ↗

Trailing P/E —

Price / Book 0.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$316.95K

↓ -84.8% —

Net Income Profit after all expenses

$-56.02M

↑ +8.2% —

FCF / Share Free cash flow per share

$-1.03

↑ +43.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	—	—	—	-84.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1160%)	-10.0% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-225%)	—	—
EPS Growth YoY (%)	37.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-8.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	1.6% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	22.4% Good Good Year-over-year change in earnings per share Optimal: > 10%	28.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	8.2% Fair ↑ Fair Improving Year-over-year change in net income	-14.1% Weak ↑ Weak Improving Year-over-year change in net income	-5.9% Weak ↑ Weak Improving Year-over-year change in net income	-50.6% Weak Weak Year-over-year change in net income	-96.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	43.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-5.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	-2.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	25.2% Excellent Excellent Year-over-year change in free cash flow	23.4% Good Good Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	—	—	—	—	0.9% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-21.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-122.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-50.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-37.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	60.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-25.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-121.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-56.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-42.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-44.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-25.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-271%)	-147.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1083%)	-59.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-494%)	-46.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-407%)	-21.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-243%)	75.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+405%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-128.65M	$-36.14M	$-59.41M	$-72.64M	$-74.89M	$-37.09M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	—	—	—	$0.01	$0.15	$0.47	—
Basic EPS, GAAP (USD)	$-1.27	$-2.04	$-1.88	$-1.91	$-2.46	$-3.44	—
Free Cash Flow per Share (USD)	$-1.03	$-1.84	$-1.74	$-1.70	$-2.27	$-2.96	—
Book Value per Share (USD)	$4.96	$1.38	$3.19	$4.16	$11.46	$-4.54	—
Tangible Book Value per Share (USD)	$4.81	$1.16	$2.95	$3.91	$10.97	$-4.54	—
Basic Weighted Avg Shares (shares)	44.01M	29.98M	28.42M	26.39M	13.61M	4.95M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$166.17M	$32.08M	$81.24M	$100.69M	$146.70M	$35.48M	—
Total Equity (USD)	$218.48M	$41.39M	$90.58M	$109.85M	$155.98M	$-22.48M	$-6.53M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	$316.95K	$2.08M	$2.31M	—
Depreciation Expense (USD)	$324.52K	$355.81K	$322.82K	$247.20K	$45.47K	$24.33K	—
Net Income, GAAP (USD)	$-56.02M	$-61.04M	$-53.47M	$-50.51M	$-33.54M	$-17.04M	—
Operating Cash Flow (USD)	$-45.34M	$-55.00M	$-48.97M	$-44.10M	$-30.85M	$-14.62M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Immuneering Corp

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare IMRX with peers